An in vitro population of human brain endothelial cells (hBECs) expressing claudin-5, occludin, ZO-1 and GLUT-1 and expressing one or more of FZD7, WNT7A, WNT7B, APCDD1, STRA6 and ZO-3 is provided. A blood brain barrier (BBB) comprising the hBECs and use of the BBB for analyzing permeability characteristics of a test agent are provided.

The present invention involves implants suitable for surgical implantation into subjects. In some embodiments the implants comprise a biocompatible scaffold material and blood vessels containing engineered endothelial cells—such as E4ORF1+ engineered endothelial cells or engineered endothelial cells that express certain marker molecules. The present invention provides implants, methods for preparing such implants, and methods of treatment utilizing such implants.

A full-function artificial organ fitting body comprises a cortex layer and an organ body tissue area. The organ body tissue area comprises a growth area, a differentiation area, a docking area, a branch arterial system, a branch nervous system and a branch venous system. The branch arterial system, the branch nervous system and the branch venous system are distributed in the differentiation area and form a main body three-dimensional skeleton structure with the outer growth area and the middle docking area.

A method for producing a three-dimensional cell structure includes preparing a mixture of a cationic substance, an extracellular matrix component, a polyelectrolyte, and a cell population including endothelial cells and mouse-derived stromal cells, which exclude mouse-derived endothelial cells, collecting a cell aggregate from the mixture, and culturing a collected cell aggregate to obtain a three-dimensional cell structure.

Multiplanar microfluidic devices are provided that facilitate direct transverse fluid communication between a first microfluidic channel a plurality of adjacent microfluidic channels, where the adjacent microfluidic channels reside both laterally adjacent and vertically adjacent to the first microfluidic channel, thereby facilitating transverse diffusion to or from the adjacent microfluidic channels in both lateral and vertical directions. Geometrical meniscus-pinning features, such as meniscus-pinning ridge structures, are provided between adjacent microfluidic channels to restrict transverse flow between the microfluidic channels. Accordingly, a gel structure may be formed within the first microfluidic channel and one or more of the adjacent microfluidic channels can function as a perfusion channel, for example, for delivering media to cells residing withing the gel structure. Such devices may be extended and/or arrayed to include multiple channels with laterally and vertically adjacent perfusion microfluidic channels, optionally with shared lateral perfusion microfluidic channels among adjacent pairs of devices.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

The present invention provides a method for culturing odontoma cells or normal cells, wherein these cells are cultured in the presence of a Rho kinase inhibitor.

A borophosphate glass composition including B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO, and optionally a source additive selected from: Li.sub.2O, Na.sub.2O, K.sub.2O, Al.sub.2O.sub.3, ZnO, MgO, Fe.sub.2O.sub.3/FeO, CuO/Cu.sub.2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO.

The present disclosure provides compositions and methods for the treatment or prophylaxis of a perfusion disorder, such as ischemia and/or reperfusion injury, in a subject's organ, tissue or extremity by preserving or improving endothelial function, reducing vascular injury, and/or promoting vascular repair. The disclosed compositions comprise endothelial colony-forming cells or a serum-free composition comprising chemically defined media conditioned by endothelial colony-forming cells.

The invention relates to a method for obtaining endothelial cells from human pluripotent stem cells.